The article reports a research on the glycogen synthase kinase-three (GSK-3) inhibitor kenpaullone drug that has been approved for the treatment of amyotrophic lateral sclerosis (ALS) and also reveals that GSK-3 increased the survival of both wild-type and SOD1G93A mice motor neurons.